fda glp-1 shortage declares semaglutide over Fierce Healthcare latest headline is quite provocative. What's your take? How What Patients Need to Know

The medication is started at a low dose and titrated up slowly to allow the body to tolerate the medication while minimizing side effects

The following five companies represent compelling acquisition targets, ranging from pure-play GLP-1 developers to adjacent pipeline builders that could diversify a metabolic-focused acquirer's portfolio into oncology, immunology, and neuroscience

This helps manage cravings, support energy levels, and aid metabolism throughout the day

The interview schedule was developed through discussion with healthcare professionals including a clinician working in a tier 3 obesity service, a diabetes physician, and a psychiatrist specialising in diabetes and mental health, as well as a member of the public with lived experience of taking a GLP-1 receptor agonist (see supplementary material p3)

and C.V

The time course of change in BMI SDS with SAXENDA and placebo from baseline through Week 56 are depicted in Figure 5